China SXT Pharmaceuticals closes $9M registered direct offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a registered direct offering raising $9 million in gross proceeds, according to a press release from placement agent Univest Securities, LLC.

The company sold 4,500,000 units to institutional investors at $2.00 per unit. Each unit consists of one Class A ordinary share and one warrant with an exercise price of $3.20 per share. The warrants are immediately exercisable upon issuance and expire one year from the issuance date.

Univest Securities, LLC served as the sole placement agent for the offering, which was made pursuant to a shelf registration statement on Form F-3 declared effective by the U.S. Securities and Exchange Commission on December 1, 2025.

China SXT Pharmaceuticals is a China-based company focused on the research, development, manufacture, and sales of traditional Chinese medicine pieces, founded in 2005 and headquartered in Taizhou City, Jiangsu Province.

You May Also Be Interested In

• Tractor Supply (TSCO) files mixed shelf
• OLB Group narrows net loss 50% as revenue falls in Q2 2026
• Cloudastructure names Nile Coates as chief revenue officer